Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 2Withdrawn 1Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Leukemia, Myeloid, Acute 8Recurrence 4Multiple Myeloma 4Leukemia, Lymphocytic, Chronic, B-Cell 4Lymphoma, Non-Hodgkin 3Leukemia 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms 2Myelodysplastic Syndromes 2Lymphoma, Large B-Cell, Diffuse 2Small Cell Lung Carcinoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Mantle-Cell 1Lymphoma 1Leukemia, Myelomonocytic, Chronic 1Immunoglobulin Light-chain Amyloidosis 1Chromosome 17 deletion 1Burkitt Lymphoma 1Amyloidosis 1

Interventions

Dexamethasone 2venetoclax 1selinexor 1ethanolamine oleate 1daratumumab 1Trimethoprim, Sulfamethoxazole Drug Combination 1Trimethoprim 1Sulfamethoxazole 1Sodium Chloride 1Saline Solution, Hypertonic 1Saline Solution 1Psychiatric Rehabilitation 1Pentetic Acid 1In Situ Hybridization, Fluorescence 1In Situ Hybridization 1Ethanol 1Edetic Acid 1Drug Therapy 1Calcium Dobesilate 1Biological Assay 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Immunoglobulin Light-chain Amyloidosis × venetoclax × Clear all
NCT05486481 2025-03-06

Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE)

University of California, San Francisco

Phase 1/2 Withdrawn
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡